Supplemental oxygen is used extensively in the treatment of pulmonary insufficiency in infants. In premature infants, hyperoxic therapies contribute to the development of bronchopulmonary dysplasia (BPD) and other multi-organ failures. The central hypothesis of the proposed study is that hepatic and pulmonary cytochrome P450 (CYP)1A enzymes play a protective role against acute and long-term injury to lung and other organs by oxygen.
The specific aims are: (1) To test the hypothesis that prenatal or postnatal exposure of wild type (WT) (C57BL/6J) mice to the cytochrome P4501A1 (CYP1A1) inducer beta-naphthoflavone (BNF) will result in attenuation or potentiation, respectively, of acute lung and liver injury and abnormal lung maturation resulting from neonatal hyperoxic exposures. Newborn wild type (WT) (C57BL/6J) mice are subjected to prenatal or postnatal treatment with corn oil (vehicle control) or BNF, and newborns will be delivered prematurethe hypothesis that newborn mice lacking the genes for CYP1A1 or the liver- specific CYP1A2 will be more susceptible to acute and long-term lung injury induced by oxygen. Newborn wild type (C57BL/6J), Cyp1a1 (-/-), Cyp1a2 (-/-), or Cyp1a1/1a2 double knockout mice will be exposed to room air or hyperoxia for 7 days, and CYP1A expression and parameters of lung and liver injury will be studied at selected time points. (3) To determine the molecular mechanism of CYP1A1 induction by hyperoxia in the newborn mice in vivo and in cultured cells.
This aim has two sub-aims: (i) To test the hypothesis that hyperoxia induces CYP1A1/1A2 gene expression in the newborn through mechanisms involving transcriptional activation of the corresponding promoters. (ii) To determine the mechanisms of induction of human CYP1A1 gene on fetal lung cells. We will test the hypothesis that hyperoxia induces CYP1A1 expression in human or mouse fetal lung cells by interaction of the AHR with specific hyperoxic respopressing the hCYP1A1 in a lung-spcific manner will be less susceptible to hyperoxic lung injury than similarly exposed WT mice. The proposed studies should provide conceptual foundation(s) for the development of novel rational strategies for the prevention and treatment of BPD and other diseases in preterm and term infants.

Public Health Relevance

Supplemental oxygen is used extensively in the treatment of pulmonary insufficiency in infants. In premature infants, hyperoxic therapies contribute to the development of bronchopulmonary dysplasia (BPD) and other multi-organ failures. Using knockout and transgenic mice, and cell culture models, this project is aimed at developing novel approaches for the prevention and treatment of lung (e.g., BPD) and other diseases associated with hyperoxia. ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL088343-04
Application #
8304343
Study Section
Special Emphasis Panel (ZRG1-DKUS-B (03))
Program Officer
Lin, Sara
Project Start
2009-09-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$379,913
Indirect Cost
$132,413
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Lingappan, Krithika; Maturu, Paramahamsa; Liang, Yanhong Wei et al. (2018) ?-Naphthoflavone treatment attenuates neonatal hyperoxic lung injury in wild type and Cyp1a2-knockout mice. Toxicol Appl Pharmacol 339:133-142
Lingappan, Krithika; Maity, Suman; Jiang, Weiwu et al. (2017) Role of Cytochrome P450 (CYP)1A in Hyperoxic Lung Injury: Analysis of the Transcriptome and Proteome. Sci Rep 7:642
Dinu, Daniela; Chu, Chun; Veith, Alex et al. (2016) Mechanistic role of cytochrome P450 (CYP)1B1 in oxygen-mediated toxicity in pulmonary cells: A novel target for prevention of hyperoxic lung injury. Biochem Biophys Res Commun 476:346-351
Wang, Lihua; Lingappan, Krithika; Jiang, Weiwu et al. (2015) Disruption of cytochrome P4501A2 in mice leads to increased susceptibility to hyperoxic lung injury. Free Radic Biol Med 82:147-59
Lingappan, Krithika; Jiang, Weiwu; Wang, Lihua et al. (2015) Sex-specific differences in hyperoxic lung injury in mice: role of cytochrome P450 (CYP)1A. Toxicology 331:14-23
Lingappan, Krithika; Jiang, Weiwu; Wang, Lihua et al. (2014) Mice deficient in the gene for cytochrome P450 (CYP)1A1 are more susceptible than wild-type to hyperoxic lung injury: evidence for protective role of CYP1A1 against oxidative stress. Toxicol Sci 141:68-77
Thakur, Vijay S; Liang, Yanhong W; Lingappan, Krithika et al. (2014) Increased susceptibility to hyperoxic lung injury and alveolar simplification in newborn rats by prenatal administration of benzo[a]pyrene. Toxicol Lett 230:322-32
Lingappan, Krithika; Srinivasan, Chandra; Jiang, Weiwu et al. (2014) Analysis of the transcriptome in hyperoxic lung injury and sex-specific alterations in gene expression. PLoS One 9:e101581
Shivanna, Binoy; Zhang, Wenyan; Jiang, Weiwu et al. (2013) Functional deficiency of aryl hydrocarbon receptor augments oxygen toxicity-induced alveolar simplification in newborn mice. Toxicol Appl Pharmacol 267:209-17
Lingappan, Krithika; Jiang, Weiwu; Wang, Lihua et al. (2013) Sex-specific differences in hyperoxic lung injury in mice: implications for acute and chronic lung disease in humans. Toxicol Appl Pharmacol 272:281-90

Showing the most recent 10 out of 11 publications